Rilpivirine

This classification denotes a reverse transcriptase inhibitor with the molecular formula C22H18N6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FI96A8X663, chemically known as 4-((4-((4-((1e)-2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile but generally known as rilpivirine, which bears US NIH Compound Identifier 6451164. European Medicines Agency schedules Rilpivirine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31456. The term RILPIVIRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, List 53). Most nations schedule rilpivirine under HS 29335995 and SITC 51576. As of Q4 2014, RILPIVIRINE remains the US FDA Preferred Term for this commodity. Rilpivirine bears US NLM identifiers UMLS ID C1566826 and NCI Concept Code C76929. SMILES: N(c1c(cc(cc1C)/C=C/C#N)C)c1nc(Nc2ccc(cc2)C#N)ncc1.